For instance, androgen deprivation therapies (ADTs), which reduce androgen levels or prevent AR role, have been reported to reduce ERG expression in TMPRSS2:ERG fusion-positive tumours, thus reducing their oncogenic potential (81). This evidence concerns the gene AR and neoplasm.